Study points to need for Group B Strep vigilance in newborns

03/21/2013 | Minnesota Public Radio

Health experts in Minnesota are expressing concern regarding an increase in cases of a drug-resistant form of Group B Streptococcus called serotype IV. The strain made up 16% of neonatal cases in 2010, according to a study published in the CDC journal Emerging Infectious Diseases. Researcher Dr. Patricia Ferrieri highlighted the importance of watching for signs of drug-resistant Group B Strep in an infant's first days of life.

View Full Article in:

Minnesota Public Radio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA